A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib
- Sponsor
- Pierre Fabre Medicament
- Study ID
- NCT05599334
- Status
- Completed
Conditions
- Adjuvant Therapy
- Breast Cancer
- HER2-positive Breast Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
The purpose of this study is to describe the demographic and clinical profiles of patients with early-stage HER2+ breast cancer treated with neratinib as an extended adjuvant therapy as part of the Early Access Program (EAP) in Europe.
Key Dates
- Start date
- Jul 5, 2022
- Status verified
- Sep 2025
- Primary completion
- Jan 30, 2023
- Completion
- Jan 30, 2023
Study Design
- Enrollment
- 111 participants (actual)
Primary Outcome Measure
Description of Age [ Time Frame: At baseline ]
Related Studies
- Collection of Blood From Patients With CancerRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Harvesting Cells for Experimental Cancer TreatmentsEnrolling By Invitation · National Cancer Institute (NCI) · Bethesda, Maryland
- High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast CancerRecruiting · Carol Fabian, MD · Kansas City, Kansas
- Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer StudiesRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland